Dennettia tripetala Relieves Chronic Hepatorenal Injuries in Rats by Altering fas, sod-1, and tnf-α Expression

The effectiveness of Dennettia tripetala extracts was compared to that of the standard drug, silymarin, in reducing chronic liver and kidney anomalies. Male albino Wistar rats were grouped in tens. Carbon tetrachloride was dissolved in olive oil (1:4) and administered to specific groups at a dose of 3 mL/kg body weight (bw) twice a week for six weeks. From week five, the extracts and silymarin were administered in distilled water daily for two weeks at doses of 250 mg/kg bw and 6 mg/kg bw, respectively, to specific groups. All administrations were carried out using a gavage, with appropriate controls. These results showed that the plant extracts decreased the serum activity of liver marker enzymes, restored the liver and serum lipid profiles as well as serum protein profile, reduced serum, urea, and creatinine, and restored superoxide dismutase and catalase activities in the liver and kidneys, which carbon tetrachloride had altered. The extracts also decreased steatosis and centriole congestion in the liver as well as necrosis and structural damage in the kidneys, which carbon tetrachloride caused, and the extracts proved to be as potent as silymarin. The extracts also decreased the expression of fas (P<0.05), sod-1 (P<0.05), and tnf-α (P>0.05) in the liver, which carbon tetrachloride had increased. Conclusively, D. tripetala reduced chronic liver and kidney damage induced by carbon tetrachloride; it reduced the expression of fas, sod-1, and tnf-α in the liver to levels similar to that of the control group, and it was as effective as silymarin.